Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Johnson & Johnson (NYSE:JNJ) is set to release earnings results for its first quarter before the opening bell on April 16, 2024.
Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.64 per share, up from $2.41 per share in the year-ago period. Johnson & Johnson is projected to report quarterly revenue of $21.40 billion, compared to $24.75 billion in the year-earlier quarter, according to data from Benzinga Pro.
Rallybio recently announced a collaboration with Johnson & Johnson to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Johnson & Johnson shares rose 0.1% to close at $147.59 on Monday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Read This Next: Brightcove And 1 Other Penny Stock Insiders Are Buying
Posted In: JNJ